TherapeuticsMD (TXMD) Cash from Operations (2010 - 2026)

TherapeuticsMD (TXMD) has reported Cash from Operations for 17 consecutive years, with $779000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 104.46% year-over-year to $779000.0; the trailing twelve-month figure through Jun 2026 stood at $3.1 million (up 201.85% YoY), and the FY2025 full-year result was $2.5 million, up 109.74% from the prior year.
• Cash from Operations slipped to $779000.0 in Q2 2026 per TXMD's latest filing, from $944000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at $30.2 million in Q4 2022 and bottomed at -$20.7 million in Q2 2022.
• Historically, Cash from Operations has averaged -$465277.8 across 5 years, with a median of $196000.0 in 2024.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations plunged 134.03% in 2023, then soared 2105.88% in 2025.
• Over 5 years, Cash from Operations stood at $30.2 million in 2022, then plunged by 116.4% to -$5.0 million in 2023, then soared by 100.34% to $17000.0 in 2024, then jumped by 2105.88% to $375000.0 in 2025, then surged by 107.73% to $779000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered $779000.0, $944000.0, and $375000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.